NCT06717022View on ClinicalTrials.gov

A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

May 31, 2039

Conditions
Mesothelin Positive Tumors
Interventions
BIOLOGICAL

CHT102 allogeneic CAR T cells

CHT102 allogeneic CAR T cells

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors
collaborator

Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.

INDUSTRY

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER